about
Unique Flap Conformation in an HIV-1 Protease with High-Level Darunavir Resistance.Discovery of MK-8718, an HIV Protease Inhibitor Containing a Novel Morpholine Aspartate Binding GroupHIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance TestingDoes antiretroviral treatment change HIV-1 codon usage patterns in its genes: a preliminary bioinformatics studyHigh prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South AfricaDevelopment and customization of a color-coded microbeads-based assay for drug resistance in HIV-1 reverse transcriptaseRecent Transmission Clustering of HIV-1 C and CRF17_BF Strains Characterized by NNRTI-Related Mutations among Newly Diagnosed Men in Central ItalyComparison of 454 Ultra-Deep Sequencing and Allele-Specific Real-Time PCR with Regard to the Detection of Emerging Drug-Resistant Minor HIV-1 Variants after Antiretroviral Prophylaxis for Vertical TransmissionLow Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort StudyVirological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in UgandaMutations Related to Antiretroviral Resistance Identified by Ultra-Deep Sequencing in HIV-1 Infected Children under Structured Interruptions of HAARTGenome-Wide Association Study of HIV Whole Genome Sequences Validated using Drug ResistanceClinical Determinants of HIV-1B Between-Host Evolution and their Association with Drug Resistance in Pediatric PatientsHIV-1 drug resistance and resistance testing.Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort studyCross-sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western IndiaHIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trialAntiviral drug resistance as an adaptive processGuidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand.Screening of the Pan-African natural product library identifies ixoratannin A-2 and boldine as novel HIV-1 inhibitors.Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor.Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening.Genetic Consequences of Antiviral Therapy on HIV-1.Long-Range HIV Genotyping Using Viral RNA and Proviral DNA for Analysis of HIV Drug Resistance and HIV Clustering.Highly resistant HIV-1 proteases and strategies for their inhibition.HIV-1 protease inhibitor drug resistance in Kenyan antiretroviral treatment-naive and -experienced injection drug users and non-drug users.Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes.Molecular Characterization of the Human Immunodeficiency Virus Type 1 in Women and Their Vertically Infected Children.Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance.Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.The Virological and Immunological Characteristics of the HIV-1-Infected Population in Brazil: From Initial Diagnosis to Impact of Antiretroviral Use.One-Step Ligation on RNA Amplification for the Detection of Point MutationsQuasispecies Analyses of the HIV-1 Near-full-length Genome With Illumina MiSeq.Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase.Conformational variation of an extreme drug resistant mutant of HIV protease.Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South AfricaQuantifying Next Generation Sequencing Sample Pre-Processing Bias in HIV-1 Complete Genome Sequencing.Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.
P2860
Q27325362-E0AE76F9-8DD3-49AF-86EF-759420FB9F9FQ27644661-EBAAC9A7-0E53-4368-8CAB-AF8C771C8B26Q28271593-9F69A892-CC84-45AF-A31E-3E9404449513Q28468602-D7CB7EDE-CB9F-4882-83FD-E54C89793F47Q28543358-3041AC5B-502A-457C-A551-8AC63471DCEBQ28543768-AF100DA0-AC65-4D35-9B03-6FF7856E2544Q28547222-009641FE-2FF0-449E-93D3-1E507E799E4BQ28550310-80BDFF8A-AD94-4475-9AAC-D2C3F907651FQ28550552-72EDA2EF-87B7-4AC6-AD5E-65CB10E930D7Q28551745-01D31614-717B-497B-ACA7-1F47527DC6FCQ28552784-07CAAE9F-DBB2-4D04-B1C7-EEB880F818DBQ28554356-927842D5-0FBC-4337-9D21-95291264ABB2Q28554672-B3923B6D-1F34-4E0E-AF4E-3050459B48A3Q30245693-5E909E0A-913D-4337-A044-16B051AC1598Q30359339-EE75FFBA-7138-4BAA-AF87-E940C8825962Q30384060-BEE5F4BD-8D3E-4FE2-9E73-23A33F534A95Q33595427-820F68A1-3635-43D0-80C2-732E255D8AFBQ33669836-B4EF4BDF-0BFF-405D-84CA-AA467948DF9AQ33788103-4BE3AC0E-9371-4D87-A618-85FEDA1B2817Q33878407-7D53CF01-18BD-4BBF-B4BD-1404F725C613Q35530299-77EA7DE1-868B-493D-9E93-E857E3954D5CQ35591789-11F5599D-9BE6-41F7-8356-792C725F40E2Q35607740-99CB9A60-6566-4A29-AB74-72CBA4637BAEQ35650700-8C223A88-0645-4988-9BAE-E9BCD33B2EE9Q35773113-866F483E-1EC7-44FD-AB02-C300345C89B4Q35868716-028B4AFA-0288-4DE3-B875-539608BE181FQ35907004-0E4E6DC6-8940-4751-9327-5C158A14E5CBQ35957224-432BCB89-C6BF-4834-8C25-AA66EC7BDFA6Q36070585-75B8AEC0-3D52-483A-B296-0EA2568ABE66Q36078446-9621BCD9-563B-4C51-93E8-0B2AE9785D31Q36146704-31E31070-B31D-4794-8200-49DB426E4331Q36185311-4ABF9DD1-4515-4FAE-9817-9BFEFA65A112Q36220805-40D86693-9653-4A0B-9A89-4AC54FC3B6A0Q36240649-C7807D4F-35C2-4A46-B406-256521C8CAE2Q36271817-1F781BEF-A6A4-4F5F-9DA7-2F9AB3DC0F56Q36290753-8EB8587D-8977-4547-A443-8A57883E4859Q36414802-9FD15B6A-CF3C-43F6-9D18-5DBFAF272182Q36463979-824FDC6B-FC1E-4656-8B13-08D81C5C91D2Q36507279-13797925-85DD-47BF-AC70-98A375CAC45CQ36543845-DBEC3FE4-2523-499E-807F-85698C388419
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
2014 Update of the drug resistance mutations in HIV-1
@en
2014 Update of the drug resistance mutations in HIV-1.
@nl
type
label
2014 Update of the drug resistance mutations in HIV-1
@en
2014 Update of the drug resistance mutations in HIV-1.
@nl
prefLabel
2014 Update of the drug resistance mutations in HIV-1
@en
2014 Update of the drug resistance mutations in HIV-1.
@nl
P2093
P2860
P1476
2014 Update of the drug resistance mutations in HIV-1
@en
P2093
Annemarie M Wensing
Douglas D Richman
Robert W Shafer
Roger Paredes
Victoria A Johnson
Vincent Calvez
P2860
P304
P577
2014-06-01T00:00:00Z